Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease

Eunjin Bae, Ran Hui Cha, Yong C. Kim, Jung N. An, Dong K. Kim, Kyung D. Yoo, Su M. Lee, Myoung Hee Kim, Jung T. Park, Shin Wook Kang, Jae Y. Park, Chun S. Lim, Yon S. Kim, Seung H. Yang, Jung P. Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) is the main public health problem in patients with chronic kidney disease (CKD); however, there is no established biomarker for predicting CVD morbidity and mortality in CKD. The aim of this study was to evaluate the role of circulating tumor necrosis factor receptors (cTNFRs) in predicting CVD risk in CKD patients. We prospectively recruited 984 patients with CKD from 11 centers between 2006 and 2012. The levels of cTNFR1 and cTNFR2 were determined by performing an enzyme-linked immunosorbent assay. During the mean follow-up period of 4 years, 36 patients experienced a CVD event. The median serum concentrations of cTNFR1 and cTNFR2 were 2703.4 (225.6-13,057.7) and 5661.0 (634.9-30,599.6)pg/mL, respectively, and the cTNFR1 level was closely correlated with the cTNFR2 level (r=0.86, P<.0001). The urinary protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate (EGFR) were significantly correlated with the cTNFR2 level (r=0.21 for UPCR, r=-0.67 for EGFR; P<.001 for all). Similar correlations were observed for serum cTNFR1 (r=0.21 for UPCR, r=-0.75 for EGFR; P<.001 for all). In the Cox proportional hazard analyses, cTNFR1 (hazard ratio [HR] 2.506, 95% confidence interval [CI] 1.186-5.295, P=.016) and cTNFR2 (HR 4.156, 95% CI 1.913-9.030, P<.001) predicted CVD risk even after adjustment for clinical covariates, such as UPCR, EGFR, and high-sensitivity C-reactive protein. cTNFR1 and 2 are associated with CVD and other risk factors in CKD, independently of EGFR and UPCR. Furthermore, cTNFRs could be relevant predictors of CVD in CKD patients.

Original languageEnglish
Article numbere6666
JournalMedicine (United States)
Volume96
Issue number19
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Tumor Necrosis Factor Receptors
Chronic Renal Insufficiency
Cardiovascular Diseases
Glomerular Filtration Rate
Creatinine
Proteins
Confidence Intervals
Serum
C-Reactive Protein
Public Health
Biomarkers
Enzyme-Linked Immunosorbent Assay
Morbidity
Mortality

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Bae, E., Cha, R. H., Kim, Y. C., An, J. N., Kim, D. K., Yoo, K. D., ... Lee, J. P. (2017). Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease. Medicine (United States), 96(19), [e6666]. https://doi.org/10.1097/MD.0000000000006666
Bae, Eunjin ; Cha, Ran Hui ; Kim, Yong C. ; An, Jung N. ; Kim, Dong K. ; Yoo, Kyung D. ; Lee, Su M. ; Kim, Myoung Hee ; Park, Jung T. ; Kang, Shin Wook ; Park, Jae Y. ; Lim, Chun S. ; Kim, Yon S. ; Yang, Seung H. ; Lee, Jung P. / Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease. In: Medicine (United States). 2017 ; Vol. 96, No. 19.
@article{39f0f997df0e426ead0f6eb44fe249b5,
title = "Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease",
abstract = "Cardiovascular disease (CVD) is the main public health problem in patients with chronic kidney disease (CKD); however, there is no established biomarker for predicting CVD morbidity and mortality in CKD. The aim of this study was to evaluate the role of circulating tumor necrosis factor receptors (cTNFRs) in predicting CVD risk in CKD patients. We prospectively recruited 984 patients with CKD from 11 centers between 2006 and 2012. The levels of cTNFR1 and cTNFR2 were determined by performing an enzyme-linked immunosorbent assay. During the mean follow-up period of 4 years, 36 patients experienced a CVD event. The median serum concentrations of cTNFR1 and cTNFR2 were 2703.4 (225.6-13,057.7) and 5661.0 (634.9-30,599.6)pg/mL, respectively, and the cTNFR1 level was closely correlated with the cTNFR2 level (r=0.86, P<.0001). The urinary protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate (EGFR) were significantly correlated with the cTNFR2 level (r=0.21 for UPCR, r=-0.67 for EGFR; P<.001 for all). Similar correlations were observed for serum cTNFR1 (r=0.21 for UPCR, r=-0.75 for EGFR; P<.001 for all). In the Cox proportional hazard analyses, cTNFR1 (hazard ratio [HR] 2.506, 95{\%} confidence interval [CI] 1.186-5.295, P=.016) and cTNFR2 (HR 4.156, 95{\%} CI 1.913-9.030, P<.001) predicted CVD risk even after adjustment for clinical covariates, such as UPCR, EGFR, and high-sensitivity C-reactive protein. cTNFR1 and 2 are associated with CVD and other risk factors in CKD, independently of EGFR and UPCR. Furthermore, cTNFRs could be relevant predictors of CVD in CKD patients.",
author = "Eunjin Bae and Cha, {Ran Hui} and Kim, {Yong C.} and An, {Jung N.} and Kim, {Dong K.} and Yoo, {Kyung D.} and Lee, {Su M.} and Kim, {Myoung Hee} and Park, {Jung T.} and Kang, {Shin Wook} and Park, {Jae Y.} and Lim, {Chun S.} and Kim, {Yon S.} and Yang, {Seung H.} and Lee, {Jung P.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1097/MD.0000000000006666",
language = "English",
volume = "96",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "19",

}

Bae, E, Cha, RH, Kim, YC, An, JN, Kim, DK, Yoo, KD, Lee, SM, Kim, MH, Park, JT, Kang, SW, Park, JY, Lim, CS, Kim, YS, Yang, SH & Lee, JP 2017, 'Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease', Medicine (United States), vol. 96, no. 19, e6666. https://doi.org/10.1097/MD.0000000000006666

Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease. / Bae, Eunjin; Cha, Ran Hui; Kim, Yong C.; An, Jung N.; Kim, Dong K.; Yoo, Kyung D.; Lee, Su M.; Kim, Myoung Hee; Park, Jung T.; Kang, Shin Wook; Park, Jae Y.; Lim, Chun S.; Kim, Yon S.; Yang, Seung H.; Lee, Jung P.

In: Medicine (United States), Vol. 96, No. 19, e6666, 01.05.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease

AU - Bae, Eunjin

AU - Cha, Ran Hui

AU - Kim, Yong C.

AU - An, Jung N.

AU - Kim, Dong K.

AU - Yoo, Kyung D.

AU - Lee, Su M.

AU - Kim, Myoung Hee

AU - Park, Jung T.

AU - Kang, Shin Wook

AU - Park, Jae Y.

AU - Lim, Chun S.

AU - Kim, Yon S.

AU - Yang, Seung H.

AU - Lee, Jung P.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Cardiovascular disease (CVD) is the main public health problem in patients with chronic kidney disease (CKD); however, there is no established biomarker for predicting CVD morbidity and mortality in CKD. The aim of this study was to evaluate the role of circulating tumor necrosis factor receptors (cTNFRs) in predicting CVD risk in CKD patients. We prospectively recruited 984 patients with CKD from 11 centers between 2006 and 2012. The levels of cTNFR1 and cTNFR2 were determined by performing an enzyme-linked immunosorbent assay. During the mean follow-up period of 4 years, 36 patients experienced a CVD event. The median serum concentrations of cTNFR1 and cTNFR2 were 2703.4 (225.6-13,057.7) and 5661.0 (634.9-30,599.6)pg/mL, respectively, and the cTNFR1 level was closely correlated with the cTNFR2 level (r=0.86, P<.0001). The urinary protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate (EGFR) were significantly correlated with the cTNFR2 level (r=0.21 for UPCR, r=-0.67 for EGFR; P<.001 for all). Similar correlations were observed for serum cTNFR1 (r=0.21 for UPCR, r=-0.75 for EGFR; P<.001 for all). In the Cox proportional hazard analyses, cTNFR1 (hazard ratio [HR] 2.506, 95% confidence interval [CI] 1.186-5.295, P=.016) and cTNFR2 (HR 4.156, 95% CI 1.913-9.030, P<.001) predicted CVD risk even after adjustment for clinical covariates, such as UPCR, EGFR, and high-sensitivity C-reactive protein. cTNFR1 and 2 are associated with CVD and other risk factors in CKD, independently of EGFR and UPCR. Furthermore, cTNFRs could be relevant predictors of CVD in CKD patients.

AB - Cardiovascular disease (CVD) is the main public health problem in patients with chronic kidney disease (CKD); however, there is no established biomarker for predicting CVD morbidity and mortality in CKD. The aim of this study was to evaluate the role of circulating tumor necrosis factor receptors (cTNFRs) in predicting CVD risk in CKD patients. We prospectively recruited 984 patients with CKD from 11 centers between 2006 and 2012. The levels of cTNFR1 and cTNFR2 were determined by performing an enzyme-linked immunosorbent assay. During the mean follow-up period of 4 years, 36 patients experienced a CVD event. The median serum concentrations of cTNFR1 and cTNFR2 were 2703.4 (225.6-13,057.7) and 5661.0 (634.9-30,599.6)pg/mL, respectively, and the cTNFR1 level was closely correlated with the cTNFR2 level (r=0.86, P<.0001). The urinary protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate (EGFR) were significantly correlated with the cTNFR2 level (r=0.21 for UPCR, r=-0.67 for EGFR; P<.001 for all). Similar correlations were observed for serum cTNFR1 (r=0.21 for UPCR, r=-0.75 for EGFR; P<.001 for all). In the Cox proportional hazard analyses, cTNFR1 (hazard ratio [HR] 2.506, 95% confidence interval [CI] 1.186-5.295, P=.016) and cTNFR2 (HR 4.156, 95% CI 1.913-9.030, P<.001) predicted CVD risk even after adjustment for clinical covariates, such as UPCR, EGFR, and high-sensitivity C-reactive protein. cTNFR1 and 2 are associated with CVD and other risk factors in CKD, independently of EGFR and UPCR. Furthermore, cTNFRs could be relevant predictors of CVD in CKD patients.

UR - http://www.scopus.com/inward/record.url?scp=85019434740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019434740&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000006666

DO - 10.1097/MD.0000000000006666

M3 - Article

C2 - 28489742

AN - SCOPUS:85019434740

VL - 96

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 19

M1 - e6666

ER -